Skip to Content
Stock Analyst Update

Enterprise Wraps Up Challenging 2020

We will maintain our $25.50 fair value estimate and wide moat rating.

Mentioned:

Enterprise Products Partners (EPD) wrapped up a challenging 2020 with a solid fourth quarter. As we expect reduced marketing opportunities in 2021 due to narrower spreads, it will be challenging for Enterprise to replicate the $500 million-$600 million in extra 2020 marketing contributions. Thus, we expect 2020 results of $8 billion in adjusted EBITDA to be repeated in 2021, as the loss in marketing contributions is offset by new projects coming online. We will maintain our $25.50 fair value estimate and wide moat rating.

Enterprise's major capital allocation efforts remained largely unchanged--2021 and 2022 growth capital spending remained set at $1.6 billion and $800 million, down from $3 billion in 2020. With distributions held nearly flat, we estimate Enterprise could have about $800 million in adjusted free cash flows after capital spending and distribution payouts to allocate toward unit buybacks or reducing leverage. Enterprise bought back $200 million in units in 2020, about 3% of its distributable cash flow, a bit above management's 2% guidance for 2020. Management cited market uncertainty at this point and wouldn't commit to a new target for 2021, but we believe there's clearly substantial opportunities for Enterprise to do so, especially given buybacks from peers such as Magellan and MPLX.

From a growth perspective, we think the best near-term opportunities lie in renewables and petrochemicals. Enterprise is evaluating several renewables investments, and also plans to source 25% of its own power needs from renewables by 2025. Petrochemicals was the strongest area of performance during the quarter, as we estimate full-year petrochemicals gross operating margin was $764 million, up from 2019's $690 million, with $222 million in the fourth quarter compared with $144 million in 2019, thanks to contributions from the new PDH plant. Enterprise is targeting a midpoint of $1.3 billion in petrochemicals gross operating margin by 2024.

Morningstar Premium Members gain exclusive access to our full analyst reports, including fair value estimates, bull and bear breakdowns, and risk analyses. Not a Premium Member? Get this and other reports immediately when you try Morningstar Premium free for 14 days.

Stephen Ellis does not own shares in any of the securities mentioned above. Find out about Morningstar’s editorial policies.

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

  • Verify your identity, personalize the content you receive, or create and administer your account.
  • Provide specific products and services to you, such as portfolio management or data aggregation.
  • Develop and improve features of our offerings.
  • Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.